Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice
Andrew George Robinson, Christopher M. Booth, Elizabeth A. Eisenhauer · European Journal of Cancer · 2014
Cited by 44 works. doi:10.1016/j.ejca.2014.05.024
Authors
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Reporting results of cancer treatment
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- Assessment of response to therapy in advanced breast cancer
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine